Stuart Kupfer
Overview
Explore the profile of Stuart Kupfer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
2768
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garcia-Pavia P, Bilen O, Burroughs M, Costabel J, de Barros Correia E, Dybro A, et al.
JACC Heart Fail
. 2025 Feb;
13(2):346-357.
PMID: 39909646
Beta-blockers and nondihydropyridine calcium-channel blockers have been standard-of-care (SOC) medications for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), even though these agents do not directly affect the underlying pathophysiology of...
2.
Xu D, Lutz J, Divanji P, Li J, Benattia Y, Griffith A, et al.
Clin Pharmacokinet
. 2025 Feb;
PMID: 39907965
Background And Objective: Aficamten, a small-molecule, selective cardiac myosin inhibitor, is under development for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Aficamten is primarily eliminated by hepatic metabolism with...
3.
Simkins T, Kupfer S, Malik F, Meng L, Rudnicki S, Wei J, et al.
Amyotroph Lateral Scler Frontotemporal Degener
. 2024 Nov;
26(1-2):103-112.
PMID: 39513379
Objective: To evaluate correlations between neurofilament (Nf) concentrations and clinical characteristics and disease progression using a large longitudinal dataset from VITALITY-ALS (ClinicalTrials.gov identifier: NCT02496767), a 48-week, randomized, double-blind, placebo-controlled clinical...
4.
Masri A, Choudhury L, Barriales-Villa R, Elliott P, Maron M, Nassif M, et al.
J Am Coll Cardiol
. 2024 Oct;
84(19):1839-1849.
PMID: 39477631
Background: Standard-of-care (SoC) medications for the treatment of obstructive hypertrophic cardiomyopathy (oHCM) are recommended as first-line therapy despite the lack of evidence from controlled clinical trials and well known off-target...
5.
Maron M, Masri A, Nassif M, Barriales-Villa R, Abraham T, Arad M, et al.
J Am Coll Cardiol
. 2024 Oct;
84(19):1821-1831.
PMID: 39352339
Background: Aficamten is a cardiac myosin inhibitor that mitigates left ventricular outflow gradients in obstructive hypertrophic cardiomyopathy (oHCM). The clinical efficacy of aficamten across multiple outcome domains in oHCM has...
6.
Lee M, Masri A, Nassif M, Barriales-Villa R, Abraham T, Claggett B, et al.
JAMA Cardiol
. 2024 Sep;
9(11):990-1000.
PMID: 39230885
Importance: Impaired exercise capacity is a cardinal manifestation of obstructive hypertrophic cardiomyopathy (HCM). The Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults...
7.
Sherrod 4th C, Saberi S, Nassif M, Claggett B, Coats C, Garcia-Pavia P, et al.
J Am Coll Cardiol
. 2024 Sep;
84(19):1773-1785.
PMID: 39217569
Background: A primary goal in treating obstructive hypertrophic cardiomyopathy (oHCM) is to improve patients' health status: their symptoms, function, and quality of life. The health status benefits of aficamten, a...
8.
Masri A, Cardoso R, Abraham T, Claggett B, Coats C, Hegde S, et al.
J Am Coll Cardiol
. 2024 Sep;
84(19):1806-1817.
PMID: 39217563
Background: Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by left ventricular (LV) hypertrophy, LV outflow tract obstruction, and left atrial dilation, which can be associated with progressive heart failure, atrial fibrillation,...
9.
Hegde S, Claggett B, Wang X, Jering K, Prasad N, Roshanali F, et al.
J Am Coll Cardiol
. 2024 Sep;
84(19):1789-1802.
PMID: 39217556
Background: Aficamten, a next-in-class cardiac myosin inhibitor, improved peak oxygen uptake (pVO) and lowered resting and Valsalva left ventricular outflow (LVOT) gradients in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM)...
10.
Coats C, Masri A, Barriales-Villa R, Abraham T, Brinkley D, Claggett B, et al.
Eur Heart J
. 2024 Sep;
45(42):4464-4478.
PMID: 39217447
Background And Aims: The role of biomarker testing in the management of obstructive hypertrophic cardiomyopathy is not well defined. This pre-specified analysis of SEQUOIA-HCM (NCT05186818) sought to define the associations...